A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies

Trial Profile

A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs CM 24 (Primary)
  • Indications Bladder cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer
  • Focus Adverse reactions; First in man
  • Sponsors cCAM Biotherapeutics; Merck Sharp & Dohme
  • Most Recent Events

    • 15 Mar 2017 Status changed from active, no longer recruiting to discontinued.
    • 23 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017.
    • 23 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top